

aap Implantate

Progression of LOQTEQ portfolio

Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m). However, US sales were above company expectations (Q3: €0.7m, 9M: €2.0m) and are indicative that the initiatives put in place to drive sales in more established markets are beginning to prove fruitful. aap Implantate will need a solid Q4 to deliver on its FY16 revenue guidance, which it now expects to be at the lower end (€13.0-15.0m).

Q316 results

aap Implantate reported sales and EBITDA in line with its guidance. It reported sales of €2.9m (guidance €2.5-4.0m) and an EBITDA loss of €1.8m (guidance loss of €1.2-2.0m). EBITDA was burdened by one-time effects due to a customer receivables value adjustment (€0.2m) and termination of a licence agreement with the co-developer of the LOQTEQ technology (€0.3m, providing sustainable relief to earnings in the long term). This resulted in a recurring EBITDA loss of €1.3m. Importantly, initiatives to drive sales in established markets are beginning to demonstrate traction, with US sales higher than management expectations and customer access in the DACH region being extended. Progress remains tempered by the missing contribution to sales in China. Continued improvement in the US remains key to the growth trajectory and to the success of the LOQTEQ portfolio.

Key areas of technology progression

LOQTEQ, aap's proprietary anatomically shaped trauma plates, continues to grow its indication coverage, recently adding periprosthetic and polyaxial ankle systems. This is important as indication expansion will enable the company to build scale that can enable bundling offers, which in turn would enable surgeons to be consistent in their treatment approach and therefore drive more conversions to the technology. aap is also actively engaged with both the European and US regulatory authorities to gain CE marking and FDA approval respectively for its antibacterial silver coating technology. aap indicates that it expects progression in 2017.

Valuation: A year of change, with upside possible

Q3 results demonstrate that aap is executing on its strategy of becoming a trauma-focused company. M&A continues to be significant in this sector and we expect a gradual shift away from scale-based acquisitions towards transactions that enhance value through innovation and enable a focus on category leadership and portfolio depth. As the company continues to drive sales of LOQTEQ in western Europe and the US, alongside the stabilisation of sales in BRICS and SMIT countries and the implementation of cost reduction measures, we could see a return to sustained growth, which could attract M&A value.

Historical financials

| Year end | Revenue (€m) | PBT (€m) | EPS (c) | DPS (c) | P/E (x) | Yield (%) |
|----------|--------------|----------|---------|---------|---------|-----------|
| 12/14 | 30.6 | (1.7) | 0.0 | 0.0 | N/A | N/A |
| 12/15 | 28.0 | (5.3) | (0.2) | 0.0 | N/A | N/A |

Source: aap Implantate accounts

Healthcare equipment & services

Price €1.27
Market cap €39m

Share price graph



Share details

Code AAQ
Listing XETRA
Shares in issue 30.8m

Business description

aap Implantate is a German medtech company, focused on developing, manufacturing and selling products for bone fractures. This is primarily the LOQTEQ trauma plating system alongside earlier-stage innovations including antibacterial silver coating technology and magnesium-based implants.

Bull

- Proven technology and strong IP protection.
- Transition to a pure trauma player enables a focus on building the core business.
- Focused on driving sales in more established markets – increased distributors in the US and an experienced head of US sales engaged.

Bear

- FY15 sales were down by 9% on FY14. Trauma sales were down 16%. Results in 2016 are indicating an improvement, but risk remains in the execution of the strategy.
- The orthopaedic space is dominated by a few large players, making it difficult for a small player to gain traction.
- Impact of increased sales focus on established markets will not be fully demonstrated until FY16 and into 2017.

Analysts

Dr Linda Pomeroy +44 (0)20 3077 5738
Lala Gregorek +44 (0)20 3681 2527

healthcare@edisongroup.com

**aap Implantate is a client of
Edison Investment Research
Limited**

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by aap Implantate and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.